Johnson & Johnson announced FDA approval of icotrokinra, to be marketed as Icotyde, for moderate-to-severe plaque psoriasis in patients 12 and older. The agency’s decision converts a once-daily oral candidate into a new commercial option versus established injectable biologics. J&J values the asset as a potential multibillion-dollar franchise and signaled plans to scale launch and patient access programs. STAT reported the approval and framed the decision in market context, noting Icotyde’s mechanism aims to replicate effects of top injectable competitors without injections. The approval follows the company’s pivotal and supporting datasets submitted to regulators and is positioned to broaden oral treatment choices for dermatology prescribers and payers.